Company profile for Variant

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

VARIANT initiated a collaborative network with various academic teams in the aim of developing diverse gene therapy approaches for treating CRX-associated retinopathies. The consortium is using complementary disease models to generate robust proofs-of-concept of therapeutic efficiency. VARIANT's proof-of-concept studies are particularly innovative. Our therapeutic strategies and drug administration methods make our product por...
VARIANT initiated a collaborative network with various academic teams in the aim of developing diverse gene therapy approaches for treating CRX-associated retinopathies. The consortium is using complementary disease models to generate robust proofs-of-concept of therapeutic efficiency. VARIANT's proof-of-concept studies are particularly innovative. Our therapeutic strategies and drug administration methods make our product portfolio highly attractive to our future partners.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
188 E Blaine St, Suite 126, Seattle, Washington, 98102, US
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/01/3159368/0/en/Spur-Therapeutics-to-Present-New-Clinical-Data-on-Its-Gene-Therapy-Candidate-in-Gaucher-Disease-at-Upcoming-ESGCT-Annual-Congress.html

GLOBENEWSWIRE
01 Oct 2025

https://www.prnewswire.com/news-releases/variant-receives-positive-feedback-from-the-european-medicines-agency-ema-for-its-innovative-gene-replacement-therapy-var002-302419848.html

PR NEWSWIRE
03 Apr 2025

https://www.prnewswire.com/news-releases/variant-bio-announces-multi-year-research-partnership-with-novo-nordisk-to-discover-novel-targets-for-metabolic-disease-302343496.html

PR NEWSWIRE
07 Jan 2025

https://www.businesswire.com/news/home/20241220584164/en

BUSINESSWIRE
20 Dec 2024

https://www.reuters.com/world/africa/zimbabwe-reports-first-two-mpox-cases-unspecified-variant-2024-10-13/

REUTERS
11 Oct 2024

https://www.reuters.com/business/healthcare-pharmaceuticals/dutch-see-bluetongue-infections-with-type-which-no-vaccine-is-available-2024-10-11/

REUTERS
11 Oct 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty